timothy sykes logo

Stock News

Is CELC Stock Overpriced?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 12/12/2025, 2:32 pm ET 12/12/2025, 2:32 pm ET | 5 min 5 min read
Is CELC Stock Overpriced? Thumbnail

Celcuity Inc.’s stocks have been trading up by 6.62 percent amid positive sentiment from recent FDA breakthrough designations.

Candlestick Chart

Live Update At 14:32:19 EST: On Friday, December 12, 2025 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 6.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Performance Overview

As millionaire penny stock trader and teacher Tim Sykes, says, “Be patient, don’t force trades, and let the perfect setups come to you.” This mindset is crucial for successful trading. Traders often feel the pressure to constantly be in the market, but it’s important to wait for the right opportunity. By exercising patience, traders can avoid unnecessary risks and increase their chances of finding profitable trades. Remember that it’s not about the number of trades you make, but the quality of those trades that ultimately leads to success in the market.

Celcuity’s recent earnings call unveiled a mixture of promising news and challenges for its financial foothold. Q3 earnings showed a loss, with an adjusted EPS of $(0.78) per share, beating analyst expectations that hovered around a $(0.96) loss. These results indicate resilience amidst significant clinical and regulatory developments surrounding their flagship drug, gedatolisib. The company’s ability to secure funding through 2027 suggests marked confidence in their future endeavors, particularly the eagerly anticipated PIK3CA mutant cohort data expected early next year.

Diving into stock performance, a look at recent trading days reveals fluctuations as it typically opened around $102 and closed slightly higher, around $107–108. This pattern indicates investor eagerness pivoting on exciting drug trial results and credible financial guidance. Despite this temporary rise, the long-term movement will heavily depend on further milestones like FDA feedback and continued profitability signals.

Key ratios paint a puzzling picture: while financial strength ratios demonstrate positive liquidity (with a current ratio of 12.3 and a quick ratio of 11.7), management effectiveness metrics highlight challenges, with negative returns across several measures—indicating growth hurdles. For instance, return on equity, at -78.35%, suggests inefficiencies that can adversely impact shareholder value.

Yet, investment strides evidenced through significant cash flow from financing (approximately $330M) offer a cushion and an opportunity kernel, harnessing optimism around development completions and expected market realities. The strategic cash management and saddled debt ratios reflect coherent plans to navigate the intensified biotech landscape.

Key News Articles Impacting CELC Stock

Gedatolisib Submission to FDA

The submission of Celcuity’s NDA under the FDA’s Real-Time Oncology Review program is a pivotal milestone with great potential. Market confidence often soars with the FDA’s expedited review processes. Should gedatolisib meet regulatory expectations, it would not only validate clinical efforts but could expand market reach significantly. The approval process, coupled with successful Phase 3 trial results, catalyzes speculation regarding imminent revenue hikes. Investors keep a sharp lookout as these are quintessential for dictating future valuations.

Analysts’ Target Price Effects

With multiple analysts raising their price targets for Celcuity, the stock market perception sways with optimism. As analysts highlight key clinical achievements and adaptive revenue guidance, their ratings serve as a beacon for retail and institutional investors alike. Momentum built around analyst sentiments can typically engender market rallies or downturns. Broader market trust, often encapsulated in these target ratings, reflects not only company performance but anticipated strategic pivots and industry dynamics.

More Breaking News

Financial Results and Market Sentiments

In a sector bursting with innovation, financial results have a palpable effect. Though Celcuity reported a substantial Q3 loss, beating expectations hinted at prudent management and productive R&D outcomes. Patience grows often lean when faced with continuous losses but forward-looking strategies and recent drug developments bolster optimistic underpinnings for market participants.

Concluding Reflections

As Celcuity maneuvers through these biopharmaceutical industry intricacies, the quest for valuation growth persists amid advances in product pipelines. Underlying stock metrics manifest trader appetites modulated by calculated risk postures. Indeed, recent performances send mixed messages—a cautionary tale urging shrewd traders to stay attuned to FDA discussions, quarterly results, and broader biotech innovations. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s not about how much money you make; it’s about how much money you keep.” With the market on the lookout, CELC’s strides invite both scrutiny and anticipation in equal measure.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”